Fireside Chat, Interview
Talks at GS – Nick Leschly: The Promise of Gene Therapy
- Bluebird Bio's core mission is to apply gene therapy to treat diseases driven by genetics by manipulating DNA to restore or engineer cellular function.
- The company's history reflects a 30-to-50-year industry period characterized by "overpromising and underdelivering," which the current leadership attributes to premature patient excitement and regulatory setbacks that previously stalled gene therapy in the US for five to ten years.
- Sickle Cell Disease Treatment
- The therapy targets a specific single mutation (valine 6 amino acid) causing sickle cell disease, a condition primarily affecting African-Americans.
- Process Mechanics
- Blood stem cells are harvested from the patient's bone marrow and removed from the body.
- A "crippled" HIV virus is utilized as a vector to insert functional DNA into the cells, enabling them to produce healthy hemoglobin.
- Patients undergo marrow ablation to eliminate competing diseased cells before the modified stem cells are reinfused.
- Outcomes and Status
- The treatment is designed as a one-time, potentially curative intervention intended to provide permanent protein production.
- Clinical data from the first patient shows a transition from severe pain requiring medication to zero pain medication (specifically Advil) within six months, with results sustained for several years.
- Therapeutic Scope and Strategy
- The technology extends beyond function restoration to function engineering, specifically applied to:
- Cancer: Engineering immune cells to identify, expand at, and destroy tumor sites.
- Autoimmune Diseases: Coupling the immune system to target and reduce autoimmune responses.
- Leadership emphasizes a "thoughtful" approach to avoid repeating past industry mistakes, explicitly excluding non-therapeutic applications like male pattern baldness.
- The technology extends beyond function restoration to function engineering, specifically applied to:
- Corporate Culture and Philosophy
- The company culture is defined by "True Blue" (compassion and patient happiness) and "Blue Mojo" (competitiveness and execution), rejecting complacency in favor of a "paranoid survival" mindset.
- The culture is anchored by the memory of Darren, a pediatric oncology patient honored as the company's "Chief Scientific Officer" for a day, serving as a constant reminder of the patient-centric mission.
- Operational Policies
- The company enforces a strict "no offices" environment and a one-word travel policy ("coach") for all employees, including the CEO, to prevent arrogance and maintain focus on patient interests.
- Hiring and firing decisions are strictly filtered through the requirement that candidates fundamentally believe in the company's mission.
- Leadership and Organizational Structure
- CEO Nick Lashley took a six-week sabbatical in Southern Spain with his family, signaling trust in the executive team and adherence to the company value of "being yourself."
- During the sabbatical, Lashley deleted 4,000 emails and reported zero negative consequences to company operations, noting that such a break would not have been feasible during active high-stakes negotiations (e.g., with L'Oreal).
- The executive structure operates with high autonomy, allowing the CEO to step away without disrupting critical workflows, a stability achieved after an earlier period of organizational instability.